Advanced search
1 file | 176.22 KB

The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)

(2010) OSTEOPOROSIS INTERNATIONAL. 21(5). p.713-722
Author
Organization
Abstract
This paper provides recommendations for fair and unbiased relationship between academic scientists and the pharmaceutical industry. Real or perceived problems in the relationship between academics and the industry have been the subject of much recent debate. It has been suggested that academic clinicians should sever all links with the industry-a view that is rarely challenged. Academic experts and members of the pharmaceutical industry were invited to an expert consensus meeting to debate this topic. This meeting was organized by the Group for the Respect of Ethics and Excellence in Science. Conflict of interest, competing interest, right and duties of academic scientist, authorship, and staff and student education were discussed. Guidelines for a transparent, ethical, strong, and successful partnership between the academic scientist and the pharmaceutical industry have been provided. The Group support interactions between the industry and clinicians provided that it is transparent and ethical.
Keywords
GOOD PUBLICATION PRACTICE, CONFLICT-OF-INTEREST, FINANCIAL CONFLICTS, BIOMEDICAL-RESEARCH, MEDICAL-EDUCATION, CLINICAL-PRACTICE, TRIAL OUTCOMES, RECOMMENDATIONS, REGISTRATION, DRUGS, Competing interest, Conflict of interest, Ethics, Ghost authorship, Medical education

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 176.22 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Bruyere, O, JA Kanis, ME Ibar-Abadie, N Alsayed, ML Brandi, N Burlet, DL Cahall, et al. 2010. “The Need for a Transparent, Ethical, and Successful Relationship Between Academic Scientists and the Pharmaceutical Industry: a View of the Group for the Respect of Ethics and Excellence in Science (GREES).” Osteoporosis International 21 (5): 713–722.
APA
Bruyere, O, Kanis, J., Ibar-Abadie, M., Alsayed, N., Brandi, M., Burlet, N., Cahall, D., et al. (2010). The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). OSTEOPOROSIS INTERNATIONAL, 21(5), 713–722.
Vancouver
1.
Bruyere O, Kanis J, Ibar-Abadie M, Alsayed N, Brandi M, Burlet N, et al. The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). OSTEOPOROSIS INTERNATIONAL. 2010;21(5):713–22.
MLA
Bruyere, O, JA Kanis, ME Ibar-Abadie, et al. “The Need for a Transparent, Ethical, and Successful Relationship Between Academic Scientists and the Pharmaceutical Industry: a View of the Group for the Respect of Ethics and Excellence in Science (GREES).” OSTEOPOROSIS INTERNATIONAL 21.5 (2010): 713–722. Print.
@article{1194268,
  abstract     = {This paper provides recommendations for fair and unbiased relationship between academic scientists and the pharmaceutical industry. Real or perceived problems in the relationship between academics and the industry have been the subject of much recent debate. It has been suggested that academic clinicians should sever all links with the industry-a view that is rarely challenged. Academic experts and members of the pharmaceutical industry were invited to an expert consensus meeting to debate this topic. This meeting was organized by the Group for the Respect of Ethics and Excellence in Science. Conflict of interest, competing interest, right and duties of academic scientist, authorship, and staff and student education were discussed. Guidelines for a transparent, ethical, strong, and successful partnership between the academic scientist and the pharmaceutical industry have been provided. The Group support interactions between the industry and clinicians provided that it is transparent and ethical.},
  author       = {Bruyere, O and Kanis, JA and Ibar-Abadie, ME and Alsayed, N and Brandi, ML and Burlet, N and Cahall, DL and Chines, A and Devogelaer, JP and Dere, W and Goel, N and Hughes, N and Kaufman, Jean and Korte, S and Mitlak, BH and Niese, D and Rizzoli, R and Rovati, LC and Reginster, JY},
  issn         = {0937-941X},
  journal      = {OSTEOPOROSIS INTERNATIONAL},
  keyword      = {GOOD PUBLICATION PRACTICE,CONFLICT-OF-INTEREST,FINANCIAL CONFLICTS,BIOMEDICAL-RESEARCH,MEDICAL-EDUCATION,CLINICAL-PRACTICE,TRIAL OUTCOMES,RECOMMENDATIONS,REGISTRATION,DRUGS,Competing interest,Conflict of interest,Ethics,Ghost authorship,Medical education},
  language     = {eng},
  number       = {5},
  pages        = {713--722},
  title        = {The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES)},
  url          = {http://dx.doi.org/10.1007/s00198-010-1190-9},
  volume       = {21},
  year         = {2010},
}

Altmetric
View in Altmetric
Web of Science
Times cited: